Arcion receives U.S. Patent allowance for ARC-2022 to treat PHN Arcion Therapeutics, a clinical stage biotechnology company developing topical therapies for chronic pain, today announced that it received see of allowance for a US Patent because of its high power gel formulation of topical lidocaine, ARC-2022. ‘With ARC-2022 our objective is to provide lidocaine to the skin without the necessity of an occlusive patch. Campbell, MD, President and CEO of Arcion. ‘We are on the right track to advance ARC-4558 for painful diabetic neuropathy into Phase 3 studies and ARC-2022 into further Phase 1/2 research in 2012. ARC-4558 has received fast-track position with the FDA.’..Related StoriesFirst medical center installs Ortho Eyesight AnalyzerLoyola Medication, Palos Community Medical center jointly start innovative telemedicine programACC's public reporting plan provides information regarding hospitals' performanceA voluntary accident strategy purchased at the place of work can help workers get a selection of benefits for back again injuries, damaged bones and even more. People who purchase a voluntary incident plan need not wait for their medical health insurance plan to pay out before they document a claim on the accident plan.